(Q39285269)

10 September 2017

title

Neuroleptic-potentiating effect of alpha-methyl-p-tyrosine compared with haloperidol and placebo in a double-blind cross-over trial (English)

2 references

10 September 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A41413

4 April 2022

Neuroleptic-potentiating effect of ?-methyl-p-tyrosine compared with haloperidol and placebo in a double-blind cross-over trial (English)

1 reference

https://api.crossref.org/works/10.1111/J.1600-0447.1979.TB03587.X

4 April 2022

1 reference

1 reference

G. Magelund

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A41413

4 April 2022

J. Gerlach

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A41413

4 April 2022

D. E. Casey

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A41413

4 April 2022

language of work or name

English

0 references

publication date

1 August 1979

1 reference

full work available at URL

10 September 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1600-0447.1979.tb03587.x

1 reference

https://api.crossref.org/works/10.1111/J.1600-0447.1979.TB03587.X

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1600-0447.1979.tb03587.x/fullpdf

4 April 2022

1 reference

https://api.crossref.org/works/10.1111/J.1600-0447.1979.TB03587.X

Acta Psychiatrica Scandinavica

4 April 2022

published in

1 reference

10 September 2017

volume

60

1 reference

10 September 2017

issue

2

1 reference

10 September 2017

page(s)

185-189

1 reference

Relationship between tardive dyskinesia, l-Dopa-induced hyperkinesia and parkinsonism

10 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1979.TB03587.X

Dopamine and the pharmacology of schizophrenia: the state of the evidence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1979.TB03587.X

Inhibition of dopamine synthesis in chronic schizophrenia. Clinical ineffectiveness of metyrosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1979.TB03587.X

Potentiation by metyrosine of thioridazine effects in chronic schizophrenics. A long-term trial using double-blind crossover technique.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1600-0447.1979.TB03587.X

Potentiation of phenothiazines by -methyltyrosine in treatment of chronic schizophrenia

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1111/J.1600-0447.1979.TB03587.X

Further studies on the mechanism of antipsychotic action: potentiation by alpha-methyltyrosine of thioridazine effects in chronic schizophrenics

4 April 2022

2

1 reference

https://api.crossref.org/works/10.1111/J.1600-0447.1979.TB03587.X

A clinical trial of a-methyl-para-tyrosine in mentally ill patients

4 April 2022

3

11

422

Charalampous K. D.

1967

1 reference

https://api.crossref.org/works/10.1111/J.1600-0447.1979.TB03587.X

Clozapine and haloperidol in a single-blind cross-over trial: therapeutic and biochemical aspects in the treatment of schizophrenia

4 April 2022

5

50

410

Gerlach J.

1974

1 reference

https://api.crossref.org/works/10.1111/J.1600-0447.1979.TB03587.X

α-Methyl-p-tyrosine (AMT) in schizophrenia

4 April 2022

6

1 reference

https://api.crossref.org/works/10.1111/J.1600-0447.1979.TB03587.X

4 April 2022

Identifiers

1 reference

10 September 2017

1 reference